Répertoire du corps professoral

iDM-scope Registre
Organisme(s) subventionnaire(s): Association française contre les myopathies
Type de financement: Subvention
Établissement tête: Université Laval
Du 6 septembre 2018 au 31 mars 2031

Financements des 2 dernières années

Recherche clinique visant à identifier les facteurs prédicateurs de la réponse au traitement de la migraine par l'Aimovig
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 30 avril 2020 au 31 mars 2025

Encadrements terminés dans les 5 dernières années

Thiéry De Serres-Bérard, Doctorat en neurosciences

Siham Ait-Benichou, Doctorat en biologie cellulaire et moléculaire

Publications des 5 dernières années

MBNL2 dysfunction in outer radial glial cells is associated with disrupted corticogenesis in congenital myotonic dystrophy. Neurobiology of disease, 2026/02/03. De Serres-Bérard T, Gosztyla ML, Nguyen G, Yeo GW, Puymirat J, Chahine M. DOI 10.1016/j.nbd.2026.107305

Generation of three myotonic dystrophy type 1 patient iPSC lines (CBRCULi018-A, CBRCULi019-A, CBRCULi020-A) derived from lymphoblastoid cell lines for disease modelling and therapeutic research. Stem cell research, 2024/03/03. Pierre M, Jauvin D, Puymirat J, Boutjdir M, Chahine M. DOI 10.1016/j.scr.2024.103375

Cardiac involvement in patient-specific induced pluripotent stem cells of myotonic dystrophy type 1: unveiling the impact of voltage-gated sodium channels. Frontiers in physiology, 2023/09/18. Pierre M, Djemai M, Chapotte-Baldacci CA, Pouliot V, Puymirat J, Boutjdir M, Chahine M. DOI 10.3389/fphys.2023.1258318

Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1. International journal of molecular sciences, 2022/11/01. De Serres-Bérard T, Ait Benichou S, Jauvin D, Boutjdir M, Puymirat J, Chahine M. DOI 10.3390/ijms232113359

Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1. Human gene therapy, 2022/08/01. Ait Benichou S, Jauvin D, De Serres-Bérard T, Bennett F, Rigo F, Gourdon G, Boutjdir M, Chahine M, Puymirat J. DOI 10.1089/hum.2022.069

Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1. Journal of neurology, 2022/02/01. Laforce RJ, Dallaire-Théroux C, Racine AM, Dent G, Salinas-Valenzuela C, Poulin E, Cayer AM, Bédard-Tremblay D, Rouleau-Bonenfant T, St-Onge F, Schraen-Maschke S, Beauregard JM, Sergeant N, Puymirat J. DOI 10.1007/s00415-022-10970-x

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1. Gene therapy, 2022/01/25. Ait Benichou S, Jauvin D, De Serres-Bérard T, Pierre M, Ling KK, Bennett CF, Rigo F, Gourdon G, Chahine M, Puymirat J. DOI 10.1038/s41434-022-00316-7

Deciphering the mechanisms underlying brain alterations and cognitive impairment in congenital myotonic dystrophy. Neurobiology of disease, 2021/10/14. De Serres-Bérard T, Pierre M, Chahine M, Puymirat J. DOI 10.1016/j.nbd.2021.105532

iPSC-derived cardiomyocytes from patients with myotonic dystrophy type 1 have abnormal ion channel functions and slower conduction velocities. Scientific reports, 2021/01/28. Poulin H, Mercier A, Djemai M, Pouliot V, Deschenes I, Boutjdir M, Puymirat J, Chahine M. DOI 10.1038/s41598-021-82007-8